Quadrigabiosciences
1 known investors
Quadriga Biosciences is developing QBS72S, a chemotherapeutic drug candidate that uses the L-type Amino Acid Transporter 1 (LAT1) to cross the blood brain barrier and enter cancer cells, where it forms DNA interstrand cross-links to kill the cells. The company focuses on novel oncology therapeutics.
BiotechHealthtech